ClinicalTrials.gg
CompletedNCT03661138Rising UpUpdated Mar 1, 2023

A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of Upadacitinib and Placebo for upadacitinib in Atopic Dermatitis, sponsored by AbbVie. Completed at 43 sites in Japan. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-01.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.

Enrollment
9th of 17
272 · median 272
Started
2018
with 3 others
Phase 3
12 of 17
none open now
Registered
6th of 17
by date
Lead sponsor
15 of 17
AbbVie

Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 9th largest by enrollment, is one of 4 that started in 2018, is one of 12 in phase 3, and was the 6th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing upadacitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety of upadacitinib combined with topical corticosteroids (TCS) in adolescent and adult participants in Japan with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Upadacitinib
  • Topical Corticosteroids
  • Atopic Dermatitis
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Body surface area (BSA), and pruritus.
  • Candidate for systemic therapy or have recently required systemic therapy for atopic dermatitis.
  • Able to tolerate topical for atopic dermatitis lesions.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any Janus kinase (JAK) inhibitor.
  • Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to the study.
  • Requirement of prohibited medications during the study.
  • Female participant who is pregnant, breastfeeding, or considering pregnancy during the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
272 participants (actual)

Study arms

  • Experimental
    Arm A

    Upadacitinib Dose A is administered once daily along with Topical Corticosteroids (TCS).

    Drug: Upadacitinib · Drug: Topical Corticosteroids (TCS)

  • Experimental
    Arm B

    Upadacitinib Dose B is administered once daily along with Topical Corticosteroids (TCS).

    Drug: Upadacitinib · Drug: Topical Corticosteroids (TCS)

  • Experimental
    Arm C

    Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.

    Drug: Upadacitinib · Drug: Placebo for upadacitinib · Drug: Topical Corticosteroids (TCS)

  • Experimental
    Arm D

    Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.

    Drug: Upadacitinib · Drug: Placebo for upadacitinib · Drug: Topical Corticosteroids (TCS)

Interventions

  • Upadacitinib is administered orally.

    Also known as: ABT-494

  • DrugPlacebo for upadacitinib

    Placebo is administered orally.

  • It is administered concomitantly with upadacitinib or placebo.

06

What researchers measure

Primary outcomes

  1. Number of participants experiencing adverse events

    Adverse events are defined as those that began or worsened in severity after the first dose of study drug but within 30 days after the last dose of study drug.

    Time frame: Up to 141 Weeks

07

Study locations

43 sites
  • Ichinomiya Municipal Hospital /ID# 205942
    Ichinomiya-shi, Aichi 491-8558, Japan
  • Nagoya City University Hospital /ID# 207566
    Nagoya shi, Aichi 467-8602, Japan
  • Central Clinic /ID# 206558
    Nagoya-shi, Aichi 464-0821, Japan
  • Yasumoto Dermatology Clinic /ID# 206480
    Chikushino-shi, Fukuoka 818-0083, Japan
  • Kiryu Dermatology Clinic /ID# 206044
    Fukuoka-shi, Fukuoka 813-0044, Japan
  • Medical Corporation Matsuo Clinic /ID# 207323
    Fukuoka-shi, Fukuoka 819-0373, Japan
  • Matsuda Tomoko Dermatological Clinic /ID# 206288
    Fukuoka-shi, Fukuoka 8190167, Japan
  • Higuchi Dermatology Urology Clinic /ID# 206287
    Kasuga-shi, Fukuoka 816-0802, Japan
  • Central Japan International Medical Center /ID# 205684
    Minokamo-shi, Gifu 505-8510, Japan
  • Kiryu Kosei General Hospital /ID# 206155
    Kiryu-shi, Gunma 376-0024, Japan
  • Gunma University Hospital /ID# 207016
    Maebashi-shi, Gunma 371-8511, Japan
  • Fukuyama City Hospital /ID# 206761
    Fukuyama-shi, Hiroshima 721-8511, Japan
  • Asahikawa Medical University Hospital /ID# 206521
    Asahikawa-shi, Hokkaido 078-8510, Japan
  • Medical Corporation Kato Dermatology Clinic /ID# 206561
    Sapporo-shi, Hokkaido 003-0026, Japan
  • Kitago Dermatology Clinic /ID# 207025
    Sapporo-shi, Hokkaido 003-0833, Japan
  • Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 206519
    Sapporo-shi, Hokkaido 060-0033, Japan
  • Kansai Rosai Hospital /ID# 205918
    Amagasaki-shi, Hyogo 660-8511, Japan
  • Hyogo Prefectural Amagasaki General Medical Center /ID# 206974
    Amagasaki-shi, Hyogo 660-8550, Japan
  • Kobe University Hospital /ID# 206200
    Kobe-shi, Hyogo 650-0017, Japan
  • Tokai University Hospital /ID# 206657
    Isehara-shi, Kanagawa 259-1193, Japan
  • Medical corporation Kojunkai Kosugi Dermatology Clinic /ID# 206766
    Kawasaki-shi, Kanagawa 211-0063, Japan
  • Nippon Medical School Musashi Kosugi Hospital /ID# 206656
    Kawasaki-shi, Kanagawa 211-8533, Japan
  • Yokohama Rosai Hospital /ID# 206648
    Yokohama-shi, Kanagawa 222-0036, Japan
  • Suizenji Dermatology Clinic /ID# 205871
    Kumamoto-shi, Kumamoto 862-0950, Japan
  • Nagasaki University Hospital /ID# 206118
    Nagasaki-shi, Nagasaki 852-8501, Japan
  • Nagaoka Red Cross Hospital /ID# 209817
    Nagaoka-shi, Niigata 940-2085, Japan
  • Isonokami dermatological clinic /ID# 206923
    Daito-shi, Osaka 574-0046, Japan
  • Medical corporation Kojinkai Yoshioka Dermatology Clinic /ID# 209704
    Neyagawa-shi, Osaka 572-0838, Japan
  • Shizuoka General Hospital /ID# 207122
    Shizuoka-shi, Shizuoka 420-8527, Japan
  • Mildix Skin Clinic /ID# 206829
    Adachi-ku, Tokyo 120-0034, Japan
  • Yaesu Nihonbashi Skin Clinic /ID# 207125
    Chuo-ku, Tokyo 103-0028, Japan
  • Fukuwa clinic /ID# 206760
    Chuo-ku, Tokyo 103-0031, Japan
  • Hosono Clinic /ID# 205953
    Chuo-ku, Tokyo 104-0031, Japan
  • Nihon University Itabashi Hospital /ID# 206186
    Itabashi-ku, Tokyo 173-8610, Japan
  • Mita Dermatology /ID# 206694
    Minato-ku, Tokyo 108-0014, Japan
  • Medical Corporation Jitai-kai Nakano Dermatology Clinic /ID# 206882
    Nakano-ku, Tokyo 164-0001, Japan
  • Matsuyama Dermatology /ID# 205998
    Nakano-ku, Tokyo 165-0026, Japan
  • Miu Skin Clinic /ID# 206911
    Ota-ku, Tokyo 114-0052, Japan
  • Tokyo Rosai Hospital /ID# 205809
    Ota-ku, Tokyo 143-0013, Japan
  • Tampopo Dermatology Clinic /ID# 207013
    Ota-ku, Tokyo 1430023, Japan
  • Naoko Dermatology Clinic /ID# 205334
    Setagaya-ku, Tokyo 158-0097, Japan
  • Tachikawa Dermatology Clinic /ID# 206996
    Tachikawa-shi, Tokyo 1900023, Japan
  • Toyama Prefectural Central Hospital /ID# 206286
    Toyama-shi, Toyama 930-8550, Japan
08

References and documents

Publications

  • Katoh N, Ohya Y, Murota H, Ikeda M, Hu X, Ikeda K, Liu J, Sasaki T, Raymundo EM, Teixeira HD, Saeki H. Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study. Dermatol Ther (Heidelb). 2023 Jan;13(1):221-234. doi: 10.1007/s13555-022-00842-7. Epub 2022 Nov 19. PubMed 36401761 ↗
  • Tanaka T, Sasaki T, Ikeda K, Liu J, Tenorio AR, Ohya Y. Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up). World Allergy Organ J. 2022 Sep 13;15(9):100678. doi: 10.1016/j.waojou.2022.100678. eCollection 2022 Sep. PubMed 36185549 ↗

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Aug 2022, 45 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 45 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2018
First posted
Sep 7, 2018
StartActual
Oct 27, 2018
Primary completionActual
Aug 19, 2022
CompletionActual
Aug 19, 2022
Last update
Mar 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03661138
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 7, 2018
Start date
Oct 27, 2018
Primary completion
Aug 19, 2022
Completion
Aug 19, 2022
Last update
Mar 1, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Upadacitinib · Topical Corticosteroid

Start the discussion